|
US3209005A
(en)
|
|
1965-09-28 |
|
Hexahydro-llbh-benzo[a]
quinolizines and processes therefor |
|
GB2410947B
(en)
|
2004-02-11 |
2008-09-17 |
Cambridge Lab Ltd |
Pharmaceutical compounds
|
|
CA2650904C
(en)
|
2006-05-02 |
2015-07-07 |
The Trustees Of The University Of Pennsylvania |
Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
|
|
EP2081929B1
(en)
|
2006-11-08 |
2013-01-09 |
Neurocrine Biosciences, Inc. |
Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
|
|
US8008500B2
(en)
|
2007-06-08 |
2011-08-30 |
General Electric Company |
Intermediates useful for making tetrabenazine compounds
|
|
US7897769B2
(en)
|
2007-10-25 |
2011-03-01 |
General Electric Company |
Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
|
|
US7910738B2
(en)
|
2007-11-29 |
2011-03-22 |
General Electric Company |
Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
|
|
US7902364B2
(en)
|
2007-11-29 |
2011-03-08 |
General Electric Company |
Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
|
|
US8053578B2
(en)
*
|
2007-11-29 |
2011-11-08 |
General Electric Company |
Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
|
|
US8013161B1
(en)
|
2007-12-07 |
2011-09-06 |
General Electric Company |
Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
|
|
US7919622B2
(en)
|
2007-12-07 |
2011-04-05 |
Kande Kankanamalage Dayarathna Amarasinghe |
Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
|
|
GB2463452A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
|
|
CA2972242A1
(en)
|
2008-09-18 |
2010-04-22 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EP3351247A1
(en)
|
2010-06-01 |
2018-07-25 |
Auspex Pharmaceutical, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
PT2836241T
(pt)
|
2012-04-10 |
2019-05-30 |
Lantheus Medical Imaging Inc |
Métodos de síntese de radiofármacos
|
|
EP4345100A3
(en)
|
2012-09-18 |
2024-04-10 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US8946255B2
(en)
|
2012-12-28 |
2015-02-03 |
Purdue Pharma L.P. |
Substituted morphinans and the use thereof
|
|
JP2016506957A
(ja)
|
2013-01-31 |
2016-03-07 |
オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｖｍａｔ２のベンゾキノロン阻害剤
|
|
US20160031840A1
(en)
|
2013-03-15 |
2016-02-04 |
University Of Kentucky Research Foundation |
1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds
|
|
GB201313291D0
(en)
|
2013-07-25 |
2013-09-11 |
Ge Healthcare Ltd |
Imaging neurological disease
|
|
WO2015077521A1
(en)
|
2013-11-22 |
2015-05-28 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EP3398602A1
(en)
|
2014-01-27 |
2018-11-07 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US9714246B2
(en)
|
2015-02-06 |
2017-07-25 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
RS61645B1
(sr)
*
|
2015-10-30 |
2021-04-29 |
Neurocrine Biosciences Inc |
Valbenazin ditozilat i njihovi polimorfi
|
|
JP6869988B2
(ja)
|
2015-12-23 |
2021-05-12 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
（Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
|
|
US11999676B2
(en)
|
2016-04-21 |
2024-06-04 |
University Of Kentucky Research Foundation |
Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
|
|
US10668030B2
(en)
|
2016-04-21 |
2020-06-02 |
University Of Kentucky Research Foundation |
Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
|
|
JOP20190239A1
(ar)
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
TW201906818A
(zh)
|
2017-05-31 |
2019-02-16 |
美商５１１製藥公司 |
新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
|
|
SG11202004165UA
(en)
|
2017-11-08 |
2020-06-29 |
Yuhua Li |
Esters of dihydrotetrabenazine
|
|
WO2020086765A1
(en)
|
2018-10-24 |
2020-04-30 |
Neurocrine Biosciences, Inc. |
Processes for preparing a vmat2 inhibitor
|
|
US12565495B2
(en)
|
2019-08-12 |
2026-03-03 |
Luye Innomind Pharma Shijiazhuang Co., Ltd. |
VMAT2 inhibitor and preparation method therefor and application thereof
|
|
US20210087191A1
(en)
|
2020-12-04 |
2021-03-25 |
Dispersol Technologies, Llc |
SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF
|
|
WO2022232380A1
(en)
|
2021-04-29 |
2022-11-03 |
Neurocrine Biosciences, Inc. |
Processes for preparing a vmat2 inhibitor
|
|
TW202322816A
(zh)
|
2021-08-20 |
2023-06-16 |
美商紐羅克里生物科學有限公司 |
篩選 vmat2 抑制劑之方法
|